Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Female
Ovarian Cancer
Female
Ovarian Cancer
Trial Information
Inclusion Criteria:
- female patients, >=18 years of age;
- epithelial ovarian, fallopian tube or primary peritoneal cancer;
- initial surgery, but no chemotherapy or radiotherapy;
- ECOG performance status of 0-2.
Exclusion Criteria:
- non-epithelial tumors;
- ovarian tumors with low malignant potential;
- previous systemic anti-cancer therapy for ovarian cancer;
- history or evidence of synchronous primary endometrial cancer;
- current or recent daily treatment with aspirin (>325mg/day) or with full dose
anticoagulant or thrombolytic agents for therapeutic purposes.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression-free survival
Outcome Time Frame:
assessed after cycles 3,6 and 9 of triple treatment and every 18 weeks on maintenance monotherapy
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Spain: Ministry of Health
Study ID:
MO22225
NCT ID:
NCT00937560
Start Date:
December 2009
Completion Date:
May 2013
Related Keywords:
- Ovarian Cancer
- Ovarian Neoplasms
Name | Location |
|---|
